The organisation currently sponsors and manages approximately 25 early phase oncology trials through its Centre for Drug Development.
By improving regulatory compliance and increasing efficiency through active trial master file (TMF) management, Cancer Research UK aims to optimise development of new treatments for patients with cancer.
“Our mission is to beat cancer sooner,” said Nigel Blackburn, Director of Drug Development at Cancer Research UK.
“Veeva Vault eTMF helps us maximise clinical trial efficiency and strengthen our commercial partnerships so we can accelerate the delivery of the next generation of treatments to the patients that need them.”
Cancer Research UK’s vision is to accelerate research so that three in four patients survive cancer by 2034. Regulatory directed drug development is key to meeting this objective.
As it continued to evaluate the effectiveness of its clinical operations, Cancer Research UK identified the opportunity to increase efficiency and quality in its management of TMF documentation and processes.
The Cancer Research UK Centre for Drug Development was previously using paper documents in a passive TMF operating model. Veeva Vault eTMF enables Cancer Research UK to manage all TMF processes and documents in one system, in real-time, as they are executed. This active TMF operating model maintains the organization’s TMF in a constant state of inspection readiness.
“Routine inspection preparation used to take as long as 12 days and archiving documentation took 40 days. Veeva Vault eTMF will allow us to complete these tasks much faster,” said Stephen Nabarro, Head of Clinical Operations and Data Management at Cancer Research UK.
“This allows our team to efficiently manage more trials, ultimately providing more early phase treatment options for people with cancer.”
Veeva Vault eTMF is a part of the Veeva Vault Clinical Suite, the industry’s first cloud platform to unify clinical data management and operations.
By combining eTMF with applications for EDC, eSource, CTMS, study start-up, and site document exchange built on the Veeva Vault Platform, organisations can eliminate system silos and streamline end-to-end clinical trial processes.
The Cancer Research UK Centre for Drug Development is celebrating 25 years of innovation and partnering with industry and academia to turn research ideas into novel therapies.
The Centre’s current development portfolio includes 11 small molecule agents and 13 biologicals. It has a track record of involvement in the development of six marketed drugs to date, including, most recently, rucaparib (Clovis Oncology) for the treatment of ovarian cancer.